Article | May 30, 2024

Streamline Microbial Process Development To Reach Toxicology Trials Faster

By Steve Loftus, Microbial Business Steering Group Lead


Microbial fermentation offers a compelling route for developing biologics, holding significant advantages for both patients and manufacturer thanks to fast processing times and cost-effective approaches when compared to traditional methods. However, it's not without its challenges. Microbial-based products are often complex molecules with unique attributes. They necessitate the development of specific, non-standardized processes for purification, demanding specialists to adapt approaches effectively.

For many startups and small biotech firms relying on venture capital or private equity funding, reaching their toxicology trial stage is a critical hurdle. This step often unlocks access to additional resources needed for further development. Thus, opting to collaborate with a CDMO that has expertise in microbial fermentation is crucial; their knowledge and experience help streamline the process development journey, especially for complex biologics. Download the full article to learn more about how an experienced CDMO can tailor a program to generate material for toxicology trials and beyond, helping to keep your eye on the prize and drug development on track.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

FUJIFILM Diosynth Biotechnologies